Cassava Sciences Inc (SAVA) Stock Price, Quote & News

Company Profile

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company w...

Industry: Biotechnology

Sector: Healthcare

Phone: 512 501 2444

Website: www.cassavasciences.com

Address:

6801 N. Capital of Texas Highway, Suite 300 Building 1, Austin, United States

BambooC Dec. 13 at 11:21 PM

$SAVA looking great from here

0 · Reply

S1mpleGOAT Dec. 13 at 8:48 PM

ARBB has only 620k shares float and is the next squeeze! Looks like shorts got trapped below and now ARBB is squeezing up! It's #1 Trending on stocktwits. ARBB could HALT UP at market open on Monday! It's getting a lot of attention.. Don't miss ARBB - It's starting its big run. Window to buy on $META $SVRA $SAVA $GEVO aswell

0 · Reply

DataJim Dec. 13 at 8:33 AM

$TLSA There seems to be a lack of trust. The fact that insiders own 40% should help, anything they do to you they’re doing to themselves. At $ZVRA your average retail shareholder owns more than half the board members. At $NGENF they raised money by selling to themselves on the cheap along with warrants. The last time I was invested in a company, I didn’t trust it was $SAVA and I definitely learned to my lesson there.

2 · Reply

ACInvestorBlog Dec. 12 at 8:37 PM

$SAVA below $3 is another buy zone for me to increase.... Huge insider buying activity , so im good with this one....

1 · Reply

TopShelf Dec. 12 at 5:21 PM

$SAVA Obviously MM at or near $3 strike

0 · Reply

holysquish Dec. 12 at 5:17 PM

$SAVA Once last dip before 20$

0 · Reply

Ottway Dec. 12 at 3:04 PM

$IGC hardly up look at $SAVA when they said they had a drug for Alzheimer’s. this is even bigger using $MJ $CGC could be biggest story in sector one day… at least worth $1 and thats 3x from here

0 · Reply

LongOrShortToMakeMoney Dec. 12 at 2:11 PM

$AVXL this is $SAVA version 2

0 · Reply

MoneyGroupLLC Dec. 12 at 6:48 AM

Enter: $SAVA Calls Strike Price: $4 Expiry Date: JAN 02 2026 Buy in Price: $0.10 - $0.30 Sell Price: $0.22 Profit : +117% (Turn every $1 into $2.17) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

bnjhnsn Dec. 11 at 10:46 PM

$SAVA regardless of of any purchases by insiders or any chart mumbo-jumbo, sava is going nowhere in the absence of major news. Having said that, im a long dreamer.

1 · Reply

Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 8:00 AM EDT - 7 weeks ago

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

Aug 14, 2025, 7:30 AM EDT - 4 months ago

Cassava Reports Q2 2025 Financials Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

Aug 4, 2025, 7:30 AM EDT - 4 months ago

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

Jun 30, 2025, 7:00 AM EDT - 5 months ago

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

May 1, 2025, 7:30 AM EDT - 8 months ago

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Apr 21, 2025, 4:30 PM EDT - 8 months ago

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Mar 26, 2025, 3:49 PM EDT - 9 months ago

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Mar 25, 2025, 10:42 AM EDT - 9 months ago

Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop

Mar 25, 2025, 8:05 AM EDT - 9 months ago

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

Mar 3, 2025, 7:30 AM EST - 10 months ago

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

Feb 9, 2025, 10:45 AM EST - 10 months ago

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

Feb 7, 2025, 12:08 PM EST - 11 months ago

SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Feb 3, 2025, 5:45 AM EST - 11 months ago

Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Jan 23, 2025, 2:47 PM EST - 11 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Jan 7, 2025, 4:30 PM EST - 1 year ago

Cassava Sciences Provides a Business Update

Dec 23, 2024, 5:45 AM EST - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

Dec 18, 2024, 10:53 AM EST - 1 year ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Dec 13, 2024, 1:16 PM EST - 1 year ago

Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Dec 10, 2024, 10:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cassava Sciences, Inc. (SAVA) Shareholders to Inquire about Securities Investigation

BambooC Dec. 13 at 11:21 PM

$SAVA looking great from here

0 · Reply

S1mpleGOAT Dec. 13 at 8:48 PM

0 · Reply

DataJim Dec. 13 at 8:33 AM

2 · Reply

ACInvestorBlog Dec. 12 at 8:37 PM

$SAVA below $3 is another buy zone for me to increase.... Huge insider buying activity , so im good with this one....

1 · Reply

TopShelf Dec. 12 at 5:21 PM

$SAVA Obviously MM at or near $3 strike

0 · Reply

holysquish Dec. 12 at 5:17 PM

$SAVA Once last dip before 20$

0 · Reply

Ottway Dec. 12 at 3:04 PM

$IGC hardly up look at $SAVA when they said they had a drug for Alzheimer’s. this is even bigger using $MJ $CGC could be biggest story in sector one day… at least worth $1 and thats 3x from here

0 · Reply

LongOrShortToMakeMoney Dec. 12 at 2:11 PM

$AVXL this is $SAVA version 2

0 · Reply

MoneyGroupLLC Dec. 12 at 6:48 AM

0 · Reply

bnjhnsn Dec. 11 at 10:46 PM

$SAVA regardless of of any purchases by insiders or any chart mumbo-jumbo, sava is going nowhere in the absence of major news. Having said that, im a long dreamer.

1 · Reply

MoneyGroupLLC Dec. 11 at 12:16 PM

Enter: $SAVA Calls Strike Price: $4 Expiry Date: JAN 02 2026 Buy in Price: $0.10 - $0.15 Sell Price: $0.19 Profit : +89% (Turn every $1 into $1.89) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

ACInvestorBlog Dec. 11 at 9:34 AM

$SAVA Open Interest per Strike and the Highest OI Increase

0 · Reply

TheRationalTrade Dec. 11 at 1:50 AM

$SAVA slowly moving up.... If it breaks 3.45 next stop is $5 (Massive gap over $5) @TheRationalTrade

0 · Reply

stu4 Dec. 11 at 12:25 AM

$CADL when you bag a pumper of his own mistakes They return to: He is a kid He lives in his mothers basement He works at Mikey D’s Almost the verbatim rhetoric of the $SAVA gang And they all were wrong !

1 · Reply

11thestate Dec. 10 at 4:29 PM

$SAVA investors — we know you’ve taken a hit. Now’s the time to find out that you can do something about those losses. Check out what we’ve got for you. https://11th.com/cases/cassavaascience-investor-suit

0 · Reply

RocketshipCalls Dec. 10 at 3:14 PM

$SAVA 🧲 The current setup (why people are watching again) You now have: • CEO buying (confidence ✅) • Compressed price (optionality ✅) • Historical squeeze behavior (volatility ✅) • One of the largest unmet medical needs in history (Alzheimer’s ✅) That’s why SAVA doesn’t die — it reloads. $SPY $BIO $SRPT Get ready for a squeeze soon! One good catalyst and we squeeze! Huge short cover incoming!

1 · Reply

holysquish Dec. 10 at 2:44 PM

$SAVA Will probably be 20$ soon

0 · Reply

Etiqute Dec. 10 at 12:40 PM

$SAVA What This Means: Positive Sentiment: Extensive insider buying signals that company executives believe the stock is undervalued or that future prospects are strong. High Confidence: This broad purchasing across multiple insiders suggests a unified belief in the company's direction.

0 · Reply

Etiqute Dec. 10 at 12:40 PM

$SAVA Key Insider Buying Activity: Richard Barry (CEO): Made numerous large purchases, including buying over 460,000 shares in late 2024/early 2025, demonstrating significant personal investment. Other Insiders: Other directors and officers, like Robert Eugene Anderson and Robert Christopher Cook, also made substantial buys. Overall Trend: The trend shows strong buying, with hundreds of thousands of shares purchased by insiders recently, and no open-market sales reported in the last 3-6 months.

0 · Reply

Etiqute Dec. 10 at 12:38 PM

$SAVA insiders at Cassava Sciences (SAVA) have been actively buying shares, with significant open-market purchases by top executives like CEO Richard Barry and other officers in late 2024 and 2025, indicating strong insider confidence with zero sales in recent months, according to data from Nasdaq, Quiver Quant, and other financial sites.

0 · Reply

RocketshipCalls Dec. 10 at 5:14 AM

$SAVA insiders buying more. Last time we saw a spike in insider buying we jumped a huge amount! Do some DD here. The CEO keeps buying thousands! I see a big news drop coming and a multi bagger here $ARVN $MIST $SPY $CTHZ

0 · Reply

MoneyGroupLLC Dec. 10 at 3:58 AM

Enter: $SAVA Calls Strike Price: $4 Expiry Date: JAN 02 2026 Buy in Price: $0.15 - $0.16 Sell Price: $0.33 Profit : +120% (Turn every $1 into $2.20) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Market Cap	141.54M
Revenue (ttm)	0.00
Net Income (ttm)	-24.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	860,500
Avg Vol	1,700,520
Day's Range	N/A - N/A
Shares Out	48.31M
Stochastic %K	10%
Beta	-1.08
Analysts	Strong Buy
Price Target	$2.00